Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib by 源��쓽�쁽 et al.
Cancer Res Treat. 2016;48(1):403-408
pISSN 1598-2998, eISSN 2005-9256
http://dx.doi.org/10.4143/crt.2014.165   
Open Access
Effective Treatment of Solitary Pituitary Metastasis with 
Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
Case Report
Brain metastasis affects one third of patients with HER2-positive breast cancer after
treatment with trastuzumab. Surgical resection and radiation therapy are often 
unsuccessful at accomplishing complete control of metastasis. Lapatinib is presumed
to cross the blood-brain barrier, and exhibits clinical activities for treatment of HER2-
positive breast cancer. A 43-year-old woman was treated for early breast carcinoma
with total mastectomy, axillary lymph-node dissection, and adjuvant chemotherapy
with cyclophosphamide plus doxorubicin. After the end of adjuvant trastuzumab ther-
apy, she was diagnosed with panhypopituitarism due to pituitary metastasis. Surgical
removal and whole brain radiation therapy were performed, but a portion of viable
tumor remained. Only taking lapatinib, the size of the metastatic lesion began to
shrink. Trastuzumab may have controlled the micro-metastasis of breast cancer, but
it was unable to control its progression to the central nervous system. Lapatinib is a
possible option for HER2-positive metastatic breast cancer patients with brain metas-
tasis.
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Introduction
Overexpression of human epidermal growth factor recep-
tor 2 (HER2) results in an aggressive form of breast cancer
[1]; however, the introduction of trastuzumab has signifi-
cantly improved the poor prognosis of this population of 
patients [2]. Although trastuzumab-based regimens are 
associated with improved control of HER2-positive metasta-
tic breast cancer, one third of trastuzumab-treated patients
still develop brain metastasis [3,4]. Trastuzumab is a large
monoclonal antibody, therefore, the drug cannot cross the
blood-brain barrier [5]. 
Pituitary metastasis is an unusual event of cancer progres-
sion, representing only 1% of pituitary lesions [6]. Approxi-
mately 30% of pituitary metastasis cases are from primary
breast cancer, and less than 10% are symptomatic. Most 
common signs of pituitary metastasis are diabetes insipidus,
hypopituitarism, visual difficulty, and headache [6,7]. There
are multiple treatment modalities for pituitary metastasis.
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Surgical resection, however, is difficult due to tumor vascu-
larity and local invasiveness [8], and radiation therapy is 
associated with substantial neurocognitive toxicity.
Lapatinib, an oral dual tyrosine kinase inhibitor of HER2
[9], has demonstrated activity in combination with capecit-
abine for treatment of HER2-positive metastatic breast cancer
that progresses after treatment with trastuzumab-containing
regimens [10-12].
Here, we report on the case of a patient with HER2-posi-
tive early breast cancer, who developed solitary pituitary
metastasis after treatment with trastuzumab. After incom-
plete surgery and whole brain radiation therapy, the metas-
tasis was controlled with lapatinib.
Case Report
A 43-year-old woman presented with polydipsia, general
weakness, gait disturbance, somnolence, and headache in
September, 2012. She was diagnosed with a stage II breast
cancer in April, 2011; a pathology report based on samples
taken during total mastectomy with axillary lymph-node 
dissection showed invasive ductal carcinoma of pT2N0M0,
which was estrogen receptor positive (moderate, 10%), prog-
esterone receptor negative, and HER2-positive (2+ by 
immunohistochemistry and amplification index 5.0 by fluo-
rescence in situ hybridization). Four cycles of adjuvant
chemotherapy with cyclophosphamide 600 mg/m2 plus 
doxorubicin 60 mg/m2 were administered, followed by one
year of adjuvant trastuzumab and daily tamoxifen therapy.
The patient presented with the same symptoms—polydipsia,
general weakness, gait disturbance, somnolence, and
headache—1 month after completing the last cycle of adju-
vant trastuzumab therapy.
Bitemporal hemianopsia was noted after her physical 
examination. No organomegaly or lymphadenopathy was
found. As shown in Table 1, laboratory investigations were
in line with the diagnosis of panhypopituitarism. Magnetic
resonance imaging (MRI) of the patient’s brain showed 
an enhancing mass in the sellar and suprasellar regions 
(Fig. 1A). She started taking hormone replacement therapy
(desmopressin acetate 50 µg twice a day, prednisolone 7.5 mg
a day, in divided doses every morning and afternoon, and
levothyroxine 75 µg a day).
Because tumor adhesion was suspected from the brain
MRI, partial removal of the tumor was performed via tran-
scranial approach. In the surgical field, the right optic nerve
was squeezed by the tumor, compressed downward by the
suprasellar main mass and upward by the stalk lesion. The
tumor was fibrous and adhesive to surrounding vessels and
nerves, therefore complete dissection of the margin was 
difficult. Pathologic reports indicated metastatic carcinoma,
which clinically originated from the breast: estrogen receptor
positive (30%), progesterone receptor negative, HER2-posi-
tive (3+ by immunohistochemistry) (Fig. 2). Whole brain 
radiation therapy (30 Gy in 12 fractions) was applied (Fig. 1B),
Table 1. Blood and urine laboratory results
Laboratory tests Value Normal value
Urine
Specific gravity 1.004 ( 1.000-1.030
Sodium (mmol/L) 11 (
Osmolality (mOsm/kg) 109 ( 20-1200
24-hr urine free cortisol (µg/day) 39.3 (L) 58-403
Serum
Osmolality (mOsm/kg) 324 ( 289-308
Sodium (mEq/L) 159 ( 135-145
Glucose (mg/dL) 143 ( 70-110
Prolactin (ng/mL) 18.7 ( 2.74-19.64
Free thyroxine (fT4) (ng/dL) 0.73 ( 0.70-1.48
Free triiodothyronine (T3) (ng/dL) 0.90 ( 0.58-1.59
Thyroid-stimulating hormone (mIU/mL) 0.04 (L) 0.35-4.94
Follicle-stimulating hormone (mIU/mL) 2.2 (L) 16.74-113.59
Luteinizing hormone (mIU/mL) < 0.2 (L) 10.87-58.64
Estradiol (pg/mL) < 20 (L) 20-40
Adrenocorticotropic hormone (pg/mL) 7.67 ( 7.2-63.3
Cortisol (µg/dL) 0.9 (L) 6.7-22.6
L, low.
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Fig. 1.  Magnetic resonance imaging of metastatic pituitary lesion. (A) At the time of diagnosis, a 35-mm strongly enhancing
mass was observed in the sellar and suprasellar regions (September 2012). (B) Even after partial removal of the tumor via
craniotomy and whole brain radiation therapy, viable tumor remained (27 mm, November 2012). (C) The size of the enhanc-
ing lesion had increased slightly (29 mm) 4 months after discontinuation of lapatinib and capecitabine due to gastrointestinal
sepsis (June 2013). (D) After re-starting lapatinib monotherapy, the size of the enhancing mass decreased (25 mm, September
2013).
A B
C D
Fig. 2.  (A) Histology of invasive ductal carcinoma showing a predominantly trabecular pattern, high nuclear atypia, and
high mitotic activity (H&E staining, !100). (B) Histology of invasive ductal carcinoma metastasis to the brain, showing 
infiltration of malignant cells to the parenchyma (H&E staining, !100).
A B
406 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2016;48(1):403-408
followed by weekly paclitaxel chemotherapy, but the patient
was unable to finish the second cycle of paclitaxel due to 
toxicity (grade 3 nausea, somnolence, and loss of memory).
Lapatinib (1,250 mg daily) plus capecitabine (2,000 mg/m2
on days 1 through 14 of a 21-day cycle) was started from 
January 2013. During the third cycle, the patient visited the
emergency room with severe septic shock due to gastroin-
testinal toxicity of lapatinib and capecitabine combination
regimen. This was an expected adverse event of the regimen.
In addition to poor general condition, her serum sodium
level changed rapidly despite treatment with desmopressin
as panhypopituitarism originated from the metastatic brain
lesion (Fig. 3). In addition, osmotic demyelination syndrome
occurred, and her mentality changed from deep stupor to
semi-comatose status for 2 months.
It took more than 3 months of rehabilitation for restoration
of the patient’s neurocognitive function; chemotherapy was
withheld during this period. Repeated MRIs showed a mild
increase in the size of the enhancing lesion in the sella,
suprasella, and the right basal ganglia (Fig. 1C). Because a
20% dose reduction of capecitabine still evoked adverse 
effects (general weakness and electrolyte imbalance),
chemotherapy with lapatinib alone was started. 
After 2 months of lapatinib monotherapy, the follow-up
MRI showed a decrease in the size of the enhancing lesion
(Fig. 1D). Repeated computed tomography of the patient’s
chest, abdomen, and pelvis did not show recurrence of 
disease in any other extra-cranial locations. The patient 
continued to suffer from visual loss and hypothalamic 
dysfunctions, including hypothermia, weight gain, and loss
of memory. However, by steadily taking lapatinib, she now
maintains a daily activity of 1 to 2 Eastern Cooperative 
Oncology Group performance score.
Discussion
This is a case involving early recurrence of breast cancer
manifested with panhypopituitarism due to metastasis to the
pituitary, pituitary stalk, and hypothalamus. The pituitary
gland is a rare site of metastasis for all neoplasms (metastasis
makes up less than 1% of pituitary tumors), and less than
10% of pituitary metastases are symptomatic [6,7]. Therefore,
the clinical history of the patient shows a rare pattern of
breast cancer metastasis.
Brain metastasis developed despite previous treatment
with trastuzumab in early stage breast cancer. Recent studies
have suggested that trastuzumab may not be active in the
central nervous system [5], which could be a potential sanc-
tuary site for disease progression in trastuzumab-treated 
patients with HER2-positive breast cancer. According to 
previous reports regarding pituitary metastasis from breast
cancer, most patients are elderly, and have clinical and/or
radiologic evidence of widespread disease, mainly to the
lymph nodes, lung and bone, at the time they are diagnosed
with pituitary metastasis [13,14]. In this case, trastuzumab
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Fig. 3.  Due to gastrointestinal sepsis, the patient’s serum sodium level changed radically (March to April, 2013), and it was
stabilized after the tumor was controlled by lapatinib (November 2013).
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may have controlled the micro-metastasis of breast cancer
after the initial total mastectomy and lymph-node dissection,
however, brain metastasis still occurred. Therefore, the 
patient experienced solitary central nervous system progres-
sion without evidence of extra-cranial lesions.
Surgery and radiation could not completely control the 
pituitary metastasis of the breast cancer. Metastatic pituitary
lesions tend to be firm, diffuse, invasive, vascular, and hem-
orrhagic; total resection of tumor is difficult [6]. Tumor 
debulking is beneficial for alleviating local symptoms, espe-
cially visual field defect and headache, whereas symptoms
such as diplopia and those related to pituitary failure remain
unaffected [6]. The patient’s quality of life was significantly
affected; she had been required to take hormone replacement
therapy every day from the time of diagnosis with pituitary
metastasis, and still suffers from loss of memory, hypother-
mia, weight gain, and complete visual loss.
Lapatinib is proven to be as active as first-line treatment
of brain metastasis from HER2-positive breast cancer in com-
bination with capecitabine [12]. It has low molecular weight,
and therefore is assumed to be able to cross the blood-brain
barrier [15]. Lapatinib and capecitabine treatment are some-
times associated with grade 3 and grade 4 toxicity (most
commonly, diarrhea and hand-foot syndrome) [12], 
however, adjustment of regimen can overcome these issues.
Widespread use of trastuzumab for treatment of HER2-
positive breast cancer leaves patients with an increased risk
of brain metastasis [3,4]. The median survival period after
central nervous system progression is about 13 months [3,4].
More follow-up is required; however, even 16 months after
the initial diagnosis of brain metastasis, the patient’s brain
lesion is well controlled with lapatinib monotherapy. There-
fore, we suggest that lapatinib is beneficial for improving the
survival and quality of life for patients with HER2-positive
brain metastasis.
Pituitary metastasis is an uncommon but serious event of
cancer progression because it can lead to pituitary insuffi-
ciency. Life-long hormone replacement therapy and deteri-
orated quality of life are inevitable. Lapatinib can be an
effective alternative therapy for managing brain metastasis
of HER2-positive breast cancer, in cases that cannot be 
completely controlled by surgery and/or radiation therapy.
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